At the time of writing, Atara Biotherapeutics Inc [ATRA] stock is trading at $13.31, up 0.23%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ATRA shares have gain 9.10% over the last week, with a monthly amount glided 9.32%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Atara Biotherapeutics Inc [NASDAQ: ATRA] stock has seen the most recent analyst activity on November 09, 2023, when Mizuho downgraded its rating to a Neutral and also revised its price target to $1 from $31. Previously, H.C. Wainwright downgraded its rating to Neutral on November 09, 2023. On November 09, 2023, downgrade downgraded it’s rating to In-line. Citigroup downgraded its rating to a Sell and decreased its price target to $3 on July 20, 2022. Stifel downgraded its rating to a Hold and reduced its price target to $5 on July 13, 2022. JP Morgan downgraded its rating to Neutral for this stock on July 13, 2022, but kept the price target unchanged to $10. In a note dated May 10, 2022, Citigroup downgraded an Neutral rating on this stock and revised its target price from $15 to $8.
For the past year, the stock price of Atara Biotherapeutics Inc fluctuated between $6.50 and $39.50. Currently, Wall Street analysts expect the stock to reach $14 within the next 12 months. Atara Biotherapeutics Inc [NASDAQ: ATRA] shares were valued at $13.31 at the most recent close of the market. An investor can expect a potential return of 5.18% based on the average ATRA price forecast.
Analyzing the ATRA fundamentals
According to Atara Biotherapeutics Inc [NASDAQ:ATRA], the company’s sales were 100.44M for trailing twelve months, which represents an 1779.79% jump. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -1.19%, Pretax Profit Margin comes in at -1.33%, and Net Profit Margin reading is -9.59%. To continue investigating profitability, this company’s Return on Assets is posted at -6.75, Equity is 9.66 and Total Capital is 9.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.75 points at the first support level, and at 12.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.73, and for the 2nd resistance point, it is at 14.14.
Ratios To Look Out For
It is important to note that Atara Biotherapeutics Inc [NASDAQ:ATRA] has a current ratio of 0.59. Also, the Quick Ratio is 0.50, while the Cash Ratio stands at 0.3. Considering the valuation of this stock, the price to sales ratio is 0.76.
Transactions by insiders
Recent insider trading involved Henrich Jill, EVP, Chief Regulatory Officer, that happened on Nov 18 ’24 when 1000.0 shares were sold. EVP, CFO and COO, Hyllengren Eric J completed a deal on Nov 18 ’24 to sell 1364.0 shares. Meanwhile, President and CEO Nguyen AnhCo sold 1664.0 shares on Nov 18 ’24.
